Updates are available Correction dated 2025-03-28
Click to view Correction: https://doi.org/10.1038/s41541-025-01108-x
-
Authors
Dudley, Matthew Z. https://orcid.org/0000-0003-1201-4066
Schuh, Holly B. https://orcid.org/0000-0002-7901-4477
Forr, Amanda
Shaw, Jana
Salmon, Daniel A.
-
Funding
Funding for this research was provided by:
Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC
Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC
Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC
Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC
Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC
- License Information
-
More Information
Article History
Received: 2 October 2023
Accepted: 1 February 2024
First Online: 28 February 2024
Change Date: 28 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41541-025-01108-x
Competing interests
: Matthew Dudley has received research support from Merck. Daniel Salmon has received research support from Merck and serves on advisory boards for Merck, Janssen, Sanofi, and Moderna. Matthew Dudley and Daniel Salmon have received funding from the Vaccination Confidence Fund, which is jointly funded by Facebook and Merck. Holly Schuh served as a (paid) health advisor to the University of Roehampton that provided guidance on recovery-building and future pandemic preparedness (including views on vaccines/vaccination) and understanding citizen engagement in the G7 in 2021-22 (during the presented study). Jana Shaw serves as a consultant to Pfizer on meningococcal B vaccine. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
